The Top 20 Promising Biotechs in the San Francisco Bay Area
The Top 20 Promising Biotechs in the San Francisco Bay Area
The Bay Area remains one of biotechnology’s most important proving grounds. What makes the current generation of companies compelling is not just the amount of capital behind them, or the number of programmes moving through the clinic, but the ambition of the problems they are trying to solve. These biotechs are making novel inroads to understand cells, redesigning immune therapies, building more precise medicines for genetically defined diseases, and rethinking how treatments can be delivered to patients.
COG: Small and Mid BioPharma Summit brings together leading trial sponsors from small, emerging and medium sized biotech companies across the San Francisco Bay Area's thriving clinical research ecosystem to advance operational excellence and innovation in clinical development.
This premier two-day gathering delivers actionable insights on strategic outsourcing and CRO selection, patient centricity, site collaboration, and the AI-driven technologies shaping the future of clinical trials.
Find Out More Here: https://www.thepbcgroup.com/cog-small-and-mid-biopharma-summit
This article highlights 20 promising Bay Area biotechs whose recent progress suggests they could help shape the next phase of life sciences innovation.
Xaira Therapeutics (South San Francisco, California)
Xaira launched in 2024 with more than $1B in committed capital and quickly became one of the most closely watched entrants in AI-driven drug discovery. Led by Marc Tessier-Lavigne, the company combines large-scale biological data generation with foundation-model research.
That work became considerably more visible in March 2026 with the launch of X-Cell, Xaira's first virtual cell model. Rather than positioning itself as a conventional drug developer, Xaira is trying to build tools that can help scientists understand how cells respond to genetic changes and identify better starting points for new medicines.
Xaira is still early and has not disclosed much of its therapeutic pipeline, but its scale and AI-first approach make it one of the clearest examples of how drug discovery is being rebuilt around biological modelling.
Structure Therapeutics (San Francisco, California)
Structure Therapeutics has spent the past year building a case that its oral small-molecule GLP-1 receptor agonist, aleniglipron, could compete with injectable treatments in obesity.
Recent clinical data has strengthened the case for aleniglipron as a potential oral alternative in a market still dominated by injectable obesity treatments. Across its mid-stage studies, Structure has reported meaningful weight-loss results and continued treatment momentum.
The broader point is simpler than the trial-by-trial numbers: Structure is trying to make metabolic disease treatment easier to take, while advancing aleniglipron in Phase III development through its ACCOMPLISH programme. If Structure can convert that progress into later-stage success, it could help make metabolic disease treatment simpler and more convenient for patients while building a broader all-oral pipeline.
Vera Therapeutics (Brisbane, California)
Vera delivered one of the Bay Area's clearest regulatory successes of 2026 when the FDA approved TRUTAKNA (atacicept-vymj) on the 7th July for adults with IgA nephropathy under the accelerated approval pathway. It became the first approved therapy targeting both BAFF and APRIL.
The approval was supported by the Phase III ORIGIN programme, which showed that atacicept could meaningfully reduce a key marker of kidney damage. For patients and clinicians, the milestone matters because it brings a new targeted option to a serious autoimmune kidney disease with significant unmet need. TRUTAKNA gives Vera its first commercial product and offers patients a new targeted option in a serious kidney disease where better treatments are still needed.
Alumis (South San Francisco, California)
Alumis is developing envudeucitinib, an oral TYK2 inhibitor that the company describes as a potential “pipeline in a pill” for immune-mediated diseases. The programme has continued to progress in psoriasis, with positive Phase III results from its ONWARD studies supporting plans for a regulatory submission. In systemic lupus erythematosus, however, the picture has been more mixed.
Alumis’ LUMUS Phase IIb study did not meet its primary or secondary endpoints in the overall population, although Alumis reported encouraging responses in a prespecified subgroup of patients with high interferon gene signature activity. They plan to discuss the findings and potential Phase III development with regulators.
Maze Therapeutics (South San Francisco, California)
Maze uses human genetics and precision small-molecule discovery to develop treatments for genetically defined diseases, particularly in kidney and metabolic medicine.
Its lead programme, MZE829, is an APOL1 inhibitor being developed for APOL1-mediated kidney disease. In March 2026, Maze reported positive topline results from the Phase II HORIZON study, describing the results as the first clinical proof of concept in a broad population of patients with APOL1-mediated kidney disease.
They have also advanced MZE782, an SLC6A19 inhibitor, into Phase II development for phenylketonuria. The programme represents another example of the company's strategy of using human genetics to identify disease mechanisms that can potentially be addressed with precision medicines. Maze shows how human genetics can guide drug discovery towards clearly defined patient populations, giving its kidney and metabolic programmes a strong biological rationale.
Marea Therapeutics (South San Francisco, California)
Marea Therapeutics is developing antibodies against genetically validated cardioendocrine targets, with cardiovascular disease and metabolic biology at the centre of its pipeline.
Its lead programme, MAR001, targets ANGPTL4, with the aim of reducing remnant cholesterol and triglycerides in people whose cardiovascular risk remains high despite standard treatment. Early clinical data have supported continued development, and the Phase IIb TYDAL-TIMI 78 study is designed to clarify how the therapy may fit into care.
Marea is also developing MAR002, a growth hormone receptor antagonist for acromegaly. In January 2026, the company reported positive Phase I data showing sustained IGF-1 suppression and a dosing profile it believes could support infrequent administration. Their approach places it at the intersection of cardiovascular and metabolic medicine, two areas attracting substantial interest across the biotech industry.
IDEAYA Biosciences (South San Francisco, California)
IDEAYA has built its identity around precision oncology, with a particular focus on genetically defined cancers.
Its lead programme, darovasertib, is being developed with crizotinib for metastatic uveal melanoma, a rare eye cancer with limited treatment options once it spreads. At ASCO 2026, IDEAYA and partner Servier presented data from its registrational Phase II/III trial that supported the combination's potential to delay disease progression and helped move the company closer to a possible regulatory submission.
IDEAYA’s second major programme, IDE849, is a DLL3-targeted antibody-drug conjugate using a topoisomerase I inhibitor payload. The programme is being evaluated in small-cell lung cancer and other neuroendocrine tumours, with further clinical data expected as development progresses.
Adicet Bio (Redwood City, California)
Adicet has increasingly focused its allogeneic gamma-delta CAR-T platform on autoimmune disease, moving beyond its earlier emphasis on oncology.
Its lead programme, prulacabtagene leucel, or prula-cel, is being investigated in lupus nephritis, systemic lupus erythematosus and systemic sclerosis. Early clinical results suggested meaningful reductions in disease activity, giving the company a reason to expand development and continue discussions with the FDA over a registration pathway.
In September 2026, Adicet announced that the last patient visit for its planned Phase I analysis had been completed, with topline results expected later in the month.
The significance of prula-cel is not simply its early efficacy signal. An allogeneic CAR-T approach that can potentially be administered without the lengthy manufacturing process associated with autologous CAR-T could offer a fundamentally different model for cell therapy in autoimmune disease.
Trace Neuroscience (South San Francisco, California)
Trace Neuroscience was named to the 2025 Fierce 15 for its work on UNC13A, a protein tied to ALS biology and a compelling target for a disease with very limited treatment options.
In June 2026, Trace initiated global clinical development of TRCN-1023, an antisense oligonucleotide designed to restore production of functional UNC13A protein. The programme includes the Phase I/II FUNCTION ALS trial in Europe and LAUNCH ALS, an investigator-initiated study in China conducted in partnership with Tenacia Biopharmaceutical. Trace states the coordinated programme is intended to accelerate development of a potential treatment for a disease with very limited therapeutic options.
It is still an early-stage programme, but the combination of a genetically validated target, a clear biological mechanism and rapid movement into human testing makes Trace one of the Bay Area's more interesting emerging neurological companies.
Nura Bio (South San Francisco, California)
Nura Bio is targeting SARM1, an enzyme involved in axon degeneration and a potential therapeutic target across multiple neurological diseases.
In June 2026, Nura Bio completed a Series B financing of $73.8M while advancing two SARM1 inhibitor programmes. Its lead candidate, NB-4746, entered clinical testing in ALS, while a second programme began an early study in healthy volunteers.
Their strategy is notable because it is attempting to address the underlying axonal degeneration process rather than targeting only individual neurological diseases.
Both programmes remain early, but the financing and move into clinical testing give Nura a credible platform-to-clinic story.
SonoThera (South San Francisco, California)
SonoThera is developing a nonviral approach to genetic medicine using ultrasound-mediated delivery.
Its RIPPLE platform uses focused ultrasound and microbubbles to deliver genetic payloads into targeted tissues, while its complementary technology is designed to support delivery of different forms of genetic medicine. The company hopes the approach can overcome some of the payload and immunogenicity limitations associated with viral vectors.
In January 2026, SonoThera announced a $125M Series B financing to advance its programmes towards clinical development. Sonothera is particularly interested in applications where conventional viral vectors struggle to deliver large genetic payloads, including Duchenne muscular dystrophy.
The technology remains preclinical, meaning its ultimate value will depend on whether the delivery system can reproduce its laboratory and animal-model performance in humans.
Cartography Biosciences (South San Francisco, California)
Cartography Biosciences is developing targeted T-cell engagers based on tumour antigens identified through its discovery platforms.
Their lead programme, CBI-1214, targets LY6G6D, a tumour-associated antigen expressed in colorectal cancer, with their objective being to identify tumour targets that are sufficiently selective to activate the immune system while limiting damage to healthy tissue.
In December 2025, the FDA cleared Cartography's IND for CBI-1214 and granted the programme Fast Track designation. The company subsequently began its first clinical trial, moving CBI-1214 into the clinic in 2026.
The programme has attracted backing from major life sciences investors, including Pfizer Ventures. Combined with its defined tumour-antigen strategy and move into the clinic, that backing makes Cartography an interesting emerging oncology company.
Centivax (South San Francisco, California)
Founded by immunologist Jacob Glanville, Centivax is developing vaccines designed to focus immune responses on conserved viral epitopes, with the long-term goal of creating broader protection than conventional strain-specific vaccines.
In February 2026, the company began dosing participants in a Phase Ia study of Centi-Flu 01, its universal influenza vaccine candidate. The study gives Centivax an important first opportunity to test whether its broad-protection vaccine concept can translate into human data.
Centivax then closed a $37M financing in March 2026 to advance the programme towards Phase II and continue development of follow-on vaccine programmes, including candidates targeting malaria and cancer. With this funding, Centivax expects to use that financing to support the next stage of Centi-Flu development and continue building the manufacturing capabilities needed for a broader vaccine platform.
Loyal (San Francisco, California)
Loyal is pursuing one of the more unusual regulatory ambitions in biotechnology: developing a drug intended specifically to extend healthy lifespan in dogs.
Its lead candidate, LOY-002, is a daily oral tablet being developed for senior dogs. Loyal has been working with the FDA's Center for Veterinary Medicine through the agency's expanded conditional approval pathway and has reported progress through key elements of its application.
In 2025, the FDA accepted Loyal's Reasonable Expectation of Effectiveness technical section, and in January 2026 the company announced that the FDA had accepted its Target Animal Safety technical section.
Loyal also raised a $100M Series C in February 2026, led by age1. Their ambition extends beyond veterinary medicine: success in dogs could provide useful evidence for the broader field of longevity research, although there is currently no guarantee that an intervention effective in dogs would translate into a human lifespan-extension therapy.
Dren Bio (Foster City, California)
Dren Bio is developing targeted therapies designed to harness the body’s myeloid cells to eliminate disease-causing cells.
Its approach has attracted significant industry interest, most notably through a 2025 agreement with Sanofi covering Dren Bio’s DR-0201 programme, which was acquired through a transaction involving Dren-0201 and is now known as SAR448501.
The deal provided significant external validation for Dren Bio’s approach while allowing the company to remain independent and continue advancing its broader pipeline. Alongside its partnered programmes, Dren Bio continues to develop therapies based on its myeloid engager technology across oncology and other disease areas.
Vaxcyte (San Carlos, California)
Vaxcyte is developing a new generation of vaccines against bacterial disease, with its lead programme, VAX-31, focused on pneumococcal disease.
VAX-31 is now being evaluated in a comprehensive Phase III programme in adults, where it is being compared with established pneumococcal vaccines. The goal is to show that a broader vaccine can protect against more strains while fitting into existing adult immunisation practice.
They are expecting topline data from its key adult study in the fourth quarter of 2026, a milestone that could determine whether VAX-31 becomes one of the most advanced next-generation vaccine programmes in the region.
Vaxcyte is also developing VAX-31 for infants and has additional vaccine programmes targeting Group A Streptococcus and Shigella. The scale of its Phase III programme and substantial financial resources make it one of the Bay Area's most advanced vaccine companies.
Synthekine (Menlo Park, California)
Synthekine engineers cytokines to selectively activate the immune cells most relevant to a disease while limiting systemic toxicity.
Its lead programme, STK-012, is an alpha/beta-biased IL-2 partial agonist designed to preferentially stimulate antigen-activated T cells. The broader strategy is to retain the anti-tumour potential of cytokine therapies such as IL-2 while improving their therapeutic window.
In 2026, Synthekine entered a clinical collaboration with Merck to evaluate STK-012 in combination with Keytruda and chemotherapy in a randomised Phase II study for first-line, PD-L1-negative, non-squamous non-small-cell lung cancer. Additionally, in August, Susan Molineaux was appointed CEO, succeeding company founder Debanjan Ray, who remains an advisor.
The programme illustrates the company's wider approach: rather than abandoning cytokine biology because of historical toxicity problems, Synthekine is attempting to redesign cytokines so that their activity can be directed towards the immune cells that matter.
Arcus Biosciences (Hayward, California)
Arcus has had a mixed year. The company discontinued two Phase III studies of its anti-TIGIT antibody domvanalimab following futility analyses, but it has increasingly concentrated resources on casdatifan, its HIF-2α inhibitor for kidney cancer.
Updated clinical data presented in February 2026 provided further support for casdatifan, in previously treated clear-cell renal cell carcinoma. The results were encouraging enough for Arcus to keep moving the programme into larger, later-stage studies.
Arcus is now advancing casdatifan through the Phase III PEAK-1 programme in immunotherapy-experienced patients and plans further Phase III development in earlier lines of treatment. Their story therefore illustrates both sides of biotech development: late-stage failure in one programme can coexist with encouraging clinical signals from another.
EpiBiologics (San Mateo, California)
EpiBiologics is developing bispecific antibodies designed to selectively degrade disease-driving proteins outside the cell through its EpiTAC platform.
Its lead candidate, EPI-326, is designed to degrade oncogenic and wild-type forms of EGFR while preferentially targeting tumour tissue. EPI-326 is initially being evaluated in non-small-cell lung cancer and head and neck cancers, with the platform also offering potential applications in other EGFR-driven tumours.
They closed a sizeable $107M Series B in January 2026 and subsequently moved EPI-326 into first-in-human clinical development, giving EpiBiologics the resources and clinical momentum to test whether its platform can work in patients.
EpiBiologics also presented preclinical EPI-326 data at AACR 2026. Those findings provided laboratory evidence supporting continued development of the programme, but should not be confused with clinical efficacy data. Their appeal lies in the possibility of applying targeted extracellular protein degradation to targets that have traditionally been difficult to address with conventional drugs.
Expedition Therapeutics (San Francisco, California)
Expedition Therapeutics is developing treatments for diseases driven by neutrophilic inflammation, with EXPD-101, an oral DPP1 inhibitor, as its lead programme.
Expedition has raised substantial funding since late 2025, giving it the capital to move EXPD-101 into Phase II development in COPD. That progress has helped the company move quickly from a young private biotech to a clinical-stage business with a defined inflammatory-disease focus.
The company's strategy is based on inhibiting DPP1, an enzyme involved in activating neutrophil serine proteases. Expedition is investigating whether this mechanism can address the inflammatory component of COPD that remains poorly controlled by existing treatments.
With its sizeable financing base and a lead programme now entering Phase II, Expedition has quickly moved from a young private biotech to one of the Bay Area's more closely watched emerging clinical companies.
Taken together, these 20 companies illustrate several of the themes shaping Bay Area biotech in 2026. Genetic validation is increasingly being translated into precision medicine, particularly in kidney, metabolic and neurological disease. Maze's APOL1 programme and Trace's UNC13A programme are examples of companies building clinical programmes around genetically defined mechanisms.
Immune engineering remains another major area of activity. Adicet is exploring allogeneic CAR-T in autoimmune disease, Synthekine is attempting to redesign cytokine biology, and Cartography is using tumour-antigen specificity to develop targeted immune therapies. The region is also home to increasingly ambitious approaches to drug discovery and delivery itself. Xaira is applying AI and large-scale perturbation data to biological modelling, while SonoThera is attempting to use ultrasound as a nonviral delivery system for genetic medicines.
Finally, several companies demonstrate that the Bay Area's biotech ecosystem is not confined to early-stage discovery. Vera has now reached commercialisation with an FDA-approved therapy, IDEAYA is pursuing regulatory approval, Vaxcyte is running a large Phase III vaccine programme and Structure is moving an oral GLP-1 candidate towards Phase III.
None of these programmes guarantees success. Clinical development remains an industry defined by attrition, and promising early data can disappear in larger trials. But the breadth of clinical, regulatory, technological and financing activity across these companies demonstrates why the Bay Area remains one of the world's most important life sciences clusters.
References:
About the Author
Rhys Wallett joined The PBC Group in October 2025 as a Conference Producer, where he researches and produces life sciences meetings for clinical-stage biopharma organisations.
In his role, Rhys develops targeted conference programs that bring together key stakeholders across the clinical research ecosystem, from CROs and pharmaceutical sponsors to biotech innovators and regulatory experts. His work focuses on identifying emerging trends in clinical development and translating complex industry challenges into actionable conference content that drives meaningful dialogue and collaboration within the life sciences community.
Comments